Translations:Biosimilar/14/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 09:54, 20 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Biosimilar)
After the expiry of the patent of approved recombinant drugs (e.g., [[insulin]], human [[growth hormone]], [[interferons]], [[erythropoietin]], monoclonal antibodies and more) any other biotech company can develop and market these [[biologic medical product|biologics]] (thus called biosimilars).

After the expiry of the patent of approved recombinant drugs (e.g., insulin, human growth hormone, interferons, erythropoietin, monoclonal antibodies and more) any other biotech company can develop and market these biologics (thus called biosimilars).

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Biosimilar/14/en&oldid=130323"